Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Scientists Discover Mechanism of Viral Link to Disease Commonly Associated with Asbestos

October 1, 1997
Publication
Article
OncologyONCOLOGY Vol 11 No 10
Volume 11
Issue 10

Cancer researchers, led by Antonio Giordano, MD, PhD, associate professor at Jefferson Medical College, have for the first

Cancer researchers, led by Antonio Giordano, MD, PhD, associate professor at Jefferson Medical College, have for the first time found direct evidence of a potential role for a monkey virus in the development of mesothelioma.

In research reported in the August 3 issue of Nature Medicine, Dr. Giordano’s team found that simian virus 40 (SV40), a DNA tumor virus from monkeys, targets key proteins that normally prevent tumors from forming, rendering them ineffective. These proteins, made by tumor-suppressor genes, are in the retinoblastoma family (pRb, pRb2/p130, and p107). SV40 T-ag binds to and inactivates the tumor-halting proteins. The discovery underscores the important role that Rb family proteins play in controlling cell growth.

“We are not saying that the virus is the only factor; clearly there is more than one factor involved in the onset of mesothelioma,” said Dr. Giordano. “It is a complex mechanism.”

According to Dr. Giordano, the finding could have important implications for developing cancer diagnostics, even a “potential test for the early development of cancer. There are implications that the pRb2/p130 gene could also be involved in the development of other cancers, such as ovarian and breast.”

Previous studies by other researchers had shown the presence of SV40 in animals and in some cases in humans. No one knew whether the virus played a direct role in causing disease, however. The discovery by Giordano's team of a potential mechanism for some cases of disease development strengthens the possible contributory role for the virus.

“Although mesothelioma is one of the most aggressive human cancers, no one had reported alterations of important cell cycle controllers, such as Rb family genes,” said Dr. Giordano. “When we studied Rb family genes in mesothelioma, we were surprised to find that the genes were present in normal levels. This led us to study why the genes are present, but not working.”

Armed with new information about SV40’s interaction with Rb family proteins, Dr. Giordano’s team is pursuing research that may lead to new treatments for mesothelioma and lung cancer. The team hopes to identify the source of SV40 infections in humans and understand how the virus is transmitted. They are also working to develop a gene therapy approach to restore growth-suppressor function of the pRb2/p130 gene. To date, the treatment has shown success in animal studies and is about to enter phase 1 clinical trials in humans.

Articles in this issue

Vinorelbine in Non-Small-Cell Lung Cancer
Paclitaxel and Vinorelbine in Non-Small-Cell Lung Cancer
Safety Data From North American Trials of Vinorelbine
Cisplatin Alone vs Cisplatin Plus Vinorelbine in Stage IV NSCLC
Doublets and Triplets: New Drug Combinations in the Palliative Care of NSCLC
Current Management of Unresectable Non-Small-Cell Lung Cancer
Concomitant Cisplatin, Vinorelbine, and Radiation in Advanced Chest Malignancies
Vinorelbine and Carboplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer
Historical Review of Trials With Vinorelbine in Non-Small-Cell Lung Cancer
The Economics of Prostate Cancer Screening
Single-Agent Pegylated Liposomal Doxorubicin in Cancer: Current Status and Future Applications
Coalition President Urges Policy Board to Focus on the Policy and Practices Affecting Cancer Research
Researchers Studying Effects of Green Tea on Cancer Patients
New Procedures Recommended for Improvement of Surgical Blood Transfusion
Possible New Approach to Brain Tumors in AIDS Patients

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Acupuncture
Related Content

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.

Adding Olanzapine to Antiemetic Therapy May Help With CINV Incidence

Roman Fabbricatore
August 4th 2024
Article

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.


Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN
May 15th 2023
Podcast

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.


Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.

Nursing-Led Palliative Cancer Care May Improve Advanced Care Planning

Hayley Virgil
April 13th 2023
Article

Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.


Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Dori Beeler, PhD;Xin Shelley Wang, MD, MPH;Viraj A. Master, MD, PhD
September 20th 2022
Podcast

Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.


Initial Data on Palliative 177Lu-FAP-2286 Highlights High Uptake and Prolonged Retention Across Several Adenocarcinomas

Initial Data on Palliative 177Lu-FAP-2286 Highlights High Uptake and Prolonged Retention Across Several Adenocarcinomas

Matthew Fowler
August 24th 2021
Article

Positive preliminary data on FAP-2286 linked to the radionuclide lutetium-177 across a diverse array of adenocarcinomas was reported from the phase 1/2 LuMIERE trial.


Qualitative Study Shares Strategies for Successful End of Life Conversations for Patients With Cancer

Qualitative Study Shares Strategies for Successful End of Life Conversations for Patients With Cancer

Ariana Pelosci
August 6th 2021
Article

Trends towards missing key moments for end-of-life discussions when meeting with patients who have stage IV cancer can be overcome with existing strategies for successful EOL conversations.

Related Content

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.

Adding Olanzapine to Antiemetic Therapy May Help With CINV Incidence

Roman Fabbricatore
August 4th 2024
Article

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.


Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN
May 15th 2023
Podcast

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.


Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.

Nursing-Led Palliative Cancer Care May Improve Advanced Care Planning

Hayley Virgil
April 13th 2023
Article

Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.


Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Dori Beeler, PhD;Xin Shelley Wang, MD, MPH;Viraj A. Master, MD, PhD
September 20th 2022
Podcast

Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.


Initial Data on Palliative 177Lu-FAP-2286 Highlights High Uptake and Prolonged Retention Across Several Adenocarcinomas

Initial Data on Palliative 177Lu-FAP-2286 Highlights High Uptake and Prolonged Retention Across Several Adenocarcinomas

Matthew Fowler
August 24th 2021
Article

Positive preliminary data on FAP-2286 linked to the radionuclide lutetium-177 across a diverse array of adenocarcinomas was reported from the phase 1/2 LuMIERE trial.


Qualitative Study Shares Strategies for Successful End of Life Conversations for Patients With Cancer

Qualitative Study Shares Strategies for Successful End of Life Conversations for Patients With Cancer

Ariana Pelosci
August 6th 2021
Article

Trends towards missing key moments for end-of-life discussions when meeting with patients who have stage IV cancer can be overcome with existing strategies for successful EOL conversations.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.